Clinical trial for Recurrent Renal Cell Carcinoma
Official title Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
ClinicalTrials.gov ID: NCT05641935
What this study is testing
What is Sulfur Hexafluoride Lipid Microspheres?
An investigational IV contrast agent being studied for use in imaging recurrent renal cell carcinoma with contrast‑enhanced ultrasound. It is designed to circulate in the bloodstream and reflect ultrasound waves, improving the visibility of blood flow and tissue structures during imaging.
Also referred to as Lumason, SF6 Lipid Microspheres, Sulfur Hexafluoride Lipid-type A Microspheres.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether contrast‑enhanced ultrasound can find kidney cancer that comes back after ablation.
- Who it's for
- You may be able to join if you have kidney cancer that has returned after a cryo or microwave ablation.
- What's involved
- You will have ultrasound scans that use a special dye to look for cancer. The scans are done at the clinic and you will not take any medication.
- Time commitment
- The study lasts a few weeks and includes a few ultrasound visits after your ablation.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Previously received cryotherapy or microwave therapy of RCC
- Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy
- Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 4 weeks of the CEUS study
- Be at least 18 years of age
- Be medically stable
You likely can't join if
- Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable
- Patients with known sensitivities to the components of Lumason
See the full eligibility criteria
- Previously received cryotherapy or microwave therapy of RCC
- Has available contrast enhanced (CE)-MRI or CE-CT imaging prior to ablative therapy
- Have previously had or are scheduled to have a contrast-enhanced MRI/CT for the monitoring of RCC recurrence within 4 weeks of the CEUS study
- Be at least 18 years of age
- Be medically stable
- If a female of child-bearing age, must have a negative pregnancy test
- Have signed Informed Consent to participate in the study
- Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable
- Patients with known sensitivities to the components of Lumason
The study team makes the final eligibility decision.
Where it is enrolling
- Philadelphia, Pennsylvania, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Philadelphia, Pennsylvania, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.